A Population-Based Study of Healthcare Resource Utilization in Patients with Mitral Valve Prolapse

Sin-Cih Chen, Sudha Xirasagar, Ju-Chi Liu, Yi-Wei Kao, Ben-Chang Shia, Tzong-Hann Yang and Herng-Ching Lin
Additional contact information
Sin-Cih Chen: School of Health Care Administration, College of Management, Taipei Medical University, Taipei 110, Taiwan
Sudha Xirasagar: Department of Health Services Policy and Management, Arnold School of Public Health, University of South Carolina, Columbia, SC 29208, USA
Ju-Chi Liu: Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan
Yi-Wei Kao: Research Center of Big Data, College of management, Taipei Medical University, Taipei 110, Taiwan
Ben-Chang Shia: Research Center of Big Data, College of management, Taipei Medical University, Taipei 110, Taiwan
Tzong-Hann Yang: Department of Otorhinolaryngology, Taipei City Hospital, Taipei 110, Taiwan
Herng-Ching Lin: School of Health Care Administration, College of Management, Taipei Medical University, Taipei 110, Taiwan

IJERPH, 2020, vol. 17, issue 5, 1-7

Abstract: This study investigated differences in the utilization of healthcare services between subjects with mitral valve prolapse (MVP) and comparison subjects using data from Taiwan’s National Health Insurance population-based database, 138,493 patients with MVP (study group) and 138,493 matched patients without MVP (comparison group). We calculated the utilization of healthcare services in the year 2016 for each study sample. Patients with MVP had more outpatient cardiological services during the year (5.3 vs. 0.7, p < 0.001) and higher outpatient cardiology costs (US$226.0 vs. US$30.8, p < 0.001) than patients without MVP. As expected, patients with MVP had a longer inpatient stay (0.5 vs. 0.1, p < 0.001) and higher inpatients costs (US$158.0 vs. US$22.9, p < 0.001) than patients without MVP for cardiology services. Furthermore, patients with MVP also had more outpatient non-cardiology services (20.8 vs. 16.5, p < 0.001) and associated costs (US$708.3 vs. US$518.7, p < 0.001) than patients without MVP in the year 2016. Multiple regression analysis indicated that patients with MVP had higher total costs for all healthcare services than patients without MVP after adjusting for the urbanization level, monthly income, and geographic region. This study demonstrated that healthcare utilization by patients with MVP is substantially higher than comparison patients. Future studies are encouraged to explore MVP treatment with less expensive modalities while maintaining care quality and without jeopardizing patient outcomes.

Keywords: mitral valve prolapse; utilization; epidemiology; big data (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2020
References: View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.mdpi.com/1660-4601/17/5/1622/pdf (application/pdf)
https://www.mdpi.com/1660-4601/17/5/1622/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:17:y:2020:i:5:p:1622-:d:327683

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().